A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)

This publication has 22 references indexed in Scilit:

• An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates
  International Journal of Pharmaceutics, 1994
• Pharmacodynamics of the Hydrolysis-Activation of the Cardioprotective Agent (+)-1,2-Bis(3,5-dioxopiperazinyl-1-yl)propane
  Journal of Pharmaceutical Sciences, 1994
• Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16)
  Biochemical Pharmacology, 1993
• Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro.
  Molecular and Cellular Biology, 1992
• Phase II Study: Treatment of Non-Hodgkin's Lymphoma With an Oral Antitumor Derivative of Bis(2,6-dioxopiperazine)
  JNCI Journal of the National Cancer Institute, 1992
• ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
  Journal of Clinical Oncology, 1992
• Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reduction
  Cancer Treatment Reviews, 1991
• Metal binding by pharmaceuticals. part 2. interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192
  Inflammation Research, 1982
• The effect of (±) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphoma
  Published by Elsevier ,1975
• Antitumour Activity in a Series of bisDiketopiperazines
  Nature, 1969